Anaplerotic reprogramming of endothelial cells in pulmonary hypertension.
肺动脉高压中内皮细胞的回补重编程。
基本信息
- 批准号:9323563
- 负责人:
- 金额:$ 38.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-01 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:3-nitrotyrosineAKT inhibitionAffectAffinityAntioxidantsApoptosisApoptoticAttenuatedBindingBlood VesselsCell ProliferationCell SurvivalCell physiologyCellular StressCessation of lifeCharacteristicsChargeCitric Acid CycleDataDiseaseEndothelial CellsEnsureEquilibriumEventFRAP1 geneHeart failureHypoxiaInhibition of ApoptosisInhibition of Cell ProliferationKnockout MiceLesionLungMalignant NeoplasmsMediatingMitochondriaModelingModificationNitratesOxaloacetatesOxidative PhosphorylationOxidative StressPDPK1 genePIK3CG genePTEN genePathologicPathway interactionsPatientsPeptidesPeroxonitritePhenotypePhosphoric Monoester HydrolasesPhosphorylationPhosphotransferasesPlayProductionProteinsPublishingPulmonary HypertensionPulmonary artery structurePyruvatePyruvate CarboxylaseRattusReactionResistanceRoleSU 5416SerineSignal TransductionStress Response SignalingStructureStructure of parenchyma of lungSuperoxidesTestingTherapeuticTyrosineVascular remodelingWorkbiological adaptation to stresscell growthendothelial dysfunctionlung hypoxiamitochondrial dysfunctionnitrationnovelpressurepulmonary arterial hypertension
项目摘要
PROJECT SUMMARY
Pulmonary arterial hypertension (PH) is a fatal disease with uncontrolled pulmonary vascular cell
proliferation. Excessive endothelial cell (EC) growth leads to the formation of plexiform lesions, which are
a characteristic cancer-like change within pulmonary arteries of patients with PH. The increased
oxidative stress in lungs of patients with PH leads to the reaction of superoxide with NO. This results in
the formation of highly reactive peroxynitrite (ONOO-) which, in turn, can produce nitro-tyrosine
modifications in proteins. Lung tissues from patients with PH have an increased level of protein nitration.
Our recently published work indicates that the nitration of tyrosine 350 residue in Akt leads to the
sustained activation of Akt signaling. The activation of Akt is a well described cell survival and stress
response but Akt activation is tightly regulated by the regulatory kinases/phosphatases (PTEN, PI3K,
PDK1 and mTOR) that control Akt activity and ensuring that it is only temporarily active. Pathological
activation of the Akt pathway has been implicated in various cancers. We hypothesize that in PH,
nitration of Akt increases translocation of eNOS to mitochondria, which downregulates oxidative
phosphorylation and activates Pyruvate Carboxylase (PC), which upregulates anaplerosis. This
activation of anaplerosis then leads to pathological hyper-proliferation of endothelial cells (EC) and
plexiform lesion formation in PH. Further, we propose to target pathological Akt signaling using an Akt-
binding peptide conjugated with an antioxidant (shielding peptide) that only affects nitration mediated Akt
activation. We will test these hypotheses in the following Aims: AIM 1: To elucidate the role of nitration
(Y350) mediated Akt activation in activation of anaplerosis in EC. AIM 2: To determine whether inhibition
of Akt nitration disrupts formation of the apoptosis resistant and proliferative EC phenotype. AIM 3: To
examine the effect of Akt shielding peptide on EC hyper-proliferation in the SU5416/hypoxia PH models.
项目摘要
肺动脉高压(pulmonary arterial hypertension,PH)是一种肺血管细胞失控的致死性疾病
增殖过度的内皮细胞(EC)生长导致丛状病变的形成,
PH患者肺动脉内的特征性癌样变化。
PH患者肺部的氧化应激导致超氧化物与NO发生反应。这导致
形成高活性过氧亚硝酸根(ONOO-),进而产生硝基酪氨酸
蛋白质的修饰。PH患者的肺组织蛋白质硝化水平增加。
我们最近发表的工作表明,Akt中酪氨酸350残基的硝化导致了Akt的蛋白质合成。
持续激活Akt信号传导。Akt的激活是细胞存活和应激的良好描述。
但是Akt的激活受到调节激酶/磷酸酶(PTEN,PI 3 K,
PDK 1和mTOR),其控制Akt活性并确保其仅暂时活跃。病理
Akt途径的激活与多种癌症有关。我们假设在PH中,
Akt的硝化作用增加eNOS向线粒体的转运,
磷酸化并激活丙酮酸羧化酶(PC),其上调回补。这
回补的激活然后导致内皮细胞(EC)的病理性过度增殖,
此外,我们建议使用Akt-1靶向病理性Akt信号传导,
结合肽与抗氧化剂(屏蔽肽)偶联,仅影响硝化介导的Akt
activation.我们将测试这些假设在以下目标:目的1:阐明硝化的作用
(Y350)介导的Akt激活在EC回补激活中的作用。目的2:确定是否抑制
Akt硝化作用破坏了细胞凋亡抗性和增殖性EC表型的形成。目标3:
在SU 5416/缺氧PH模型中检测Akt屏蔽肽对EC过度增殖的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ruslan Rafikov其他文献
Ruslan Rafikov的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ruslan Rafikov', 18)}}的其他基金
Hemolysis and free heme signaling in pulmonary hypertension
肺动脉高压中的溶血和游离血红素信号传导
- 批准号:
10402254 - 财政年份:2020
- 资助金额:
$ 38.38万 - 项目类别:
Hemolysis and free heme signaling in pulmonary hypertension
肺动脉高压中的溶血和游离血红素信号传导
- 批准号:
10152669 - 财政年份:2020
- 资助金额:
$ 38.38万 - 项目类别:
Hemolysis and free heme signaling in pulmonary hypertension
肺动脉高压中的溶血和游离血红素信号传导
- 批准号:
10653822 - 财政年份:2020
- 资助金额:
$ 38.38万 - 项目类别:
Anaplerotic reprogramming of endothelial cells in pulmonary hypertension
肺动脉高压中内皮细胞的回补重编程
- 批准号:
10634626 - 财政年份:2016
- 资助金额:
$ 38.38万 - 项目类别:
Anaplerotic reprogramming of endothelial cells in pulmonary hypertension
肺动脉高压中内皮细胞的回补重编程
- 批准号:
10441800 - 财政年份:2016
- 资助金额:
$ 38.38万 - 项目类别:
Anaplerotic reprogramming of endothelial cells in pulmonary hypertension.
肺动脉高压中内皮细胞的回补重编程。
- 批准号:
9154826 - 财政年份:2016
- 资助金额:
$ 38.38万 - 项目类别:
相似海外基金
Elucidating resistance to AKT inhibition in metastatic breast cancer
阐明转移性乳腺癌对 AKT 抑制的耐药性
- 批准号:
2440937 - 财政年份:2020
- 资助金额:
$ 38.38万 - 项目类别:
Studentship
The Risk of Novel AKT Inhibition on Lethal Neuroendocrine Prostate Cancer Development
新型 AKT 抑制对致死性神经内分泌前列腺癌发展的风险
- 批准号:
350042 - 财政年份:2015
- 资助金额:
$ 38.38万 - 项目类别:
Studentship Programs
Mechanistic studies of cancer cell adaptive response to PI3K/AKT inhibition
癌细胞对 PI3K/AKT 抑制的适应性反应的机制研究
- 批准号:
9272854 - 财政年份:2015
- 资助金额:
$ 38.38万 - 项目类别:
Targeting RAS signaling with CDK and AKT inhibition in pancreatic cancer
通过 CDK 和 AKT 抑制作用靶向胰腺癌中的 RAS 信号传导
- 批准号:
8581465 - 财政年份:2013
- 资助金额:
$ 38.38万 - 项目类别:
Targeting RAS signaling with CDK and AKT inhibition in pancreatic cancer
通过 CDK 和 AKT 抑制作用靶向胰腺癌中的 RAS 信号传导
- 批准号:
8692694 - 财政年份:2013
- 资助金额:
$ 38.38万 - 项目类别: